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Abstract   
Background: The morphological evaluation of tumor infiltrating lymphocytes (TILs) in breast 
cancer is gaining momentum as evidence strengthens for the clinical relevance of this 
immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic 
infiltration in tumor tissue can be assessed as a major parameter by evaluation of (H&E) 
hematoxylin and eosin-stained tumor sections. TILs have been shown to provide prognostic and 
potentially predictive value, particularly in triple negative and HER2-overexpressing breast 
cancer.  
Design: A standardized methodology for evaluating TILs is now needed as a prerequisite for 
integrating this parameter in standard histopathological practice, in a research setting as well as 
in clinical trials. This article reviews current data on the clinical validity and utility of TILs in breast 
cancer in an effort to foster better knowledge and insight in this rapidly evolving field, and to 
develop a standardized methodology for visual assessment on H&E-sections, acknowledging 
the future potential of molecular/multiplexed approaches.  
Conclusion: The methodology provided is sufficiently detailed to offer a uniformly applied, 
pragmatic starting point and improve consistency and reproducibility in the measurement of TILs 
for future studies.  
 
Key words 
Tumor infiltrating lymphocytes (TILs), breast cancer (BC), prognosis, prediction, clinical validity. 
Word count:  4401 words (Microsoft Word 2010). 
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Key message 
Several translational studies based on phase III clinical trials have demonstrated that stromal 
tumor infiltrating lymphocytes (TILs) are a robust prognostic factor in TNBC. For HER2-positive 
breast cancer, TILs in baseline samples have been associated with higher responses to 
trastuzumab and chemotherapy treatment. There is therefore a need for harmonizing the 
histological approach to assess the percentage of stromal TILs in primary tumor specimens prior 
to therapy. The goal of this article is to facilitate the use of TILs as a biomarker in research and 
clinical trial settings, and ultimately in diagnostic practice. Herein, the current fundamental 
concepts for TILs-evaluation are laid out by pathologists to foster their widespread use and 
consistent interpretation at this early stage. The recommendations illustrated in this manuscript 
focus on: 1) what areas to examine in the tumor, 2) how to score the TILs, and 3) why TILs are 
clinically relevant. This information should provide a platform for pathologists to further engage in 
efforts leading to procedural standardization of this biomarker assay. 
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Context of research:  
A panel of pathology, clinical oncology, biostatisticians and translational research experts 
conducted a systematic review of the literature. Panel members invited have had experience in 
TIL-assessment in phase III-trials or are involved in breast cancer translational research focused 
on the interactions between immunology and breast cancer. There are no existing guidelines on 
TIL-assessment in breast cancer available for comparison; neither is there proficiency testing 
data available from international organizations. No specific funding was obtained for this project. 
For details on prognosis, prospective-retrospective phase III trials were the main basis for these 
recommendations. However, we searched PubMed from Jan 1 2009 to April 30 2014 for full 
reports of studies involving clinical trial datasets or large institutional cohorts and evaluation of 
TILs, CD8+, CD3+ or immune gene signatures in primary breast cancer. Studies were not 
limited to randomized trials, but included also large consecutive and retrospective series. In-
press publications were also taken into consideration. With regards to specific TILs pathological 
assessment, the panel undertook a formal expert consensus–based process by regular mail, 
teleconferences as well as two F2F-meetings by the writing committee (RS, SL, SdM, KWG, SA) 
to produce these recommendations. Draft manuscripts were circulated by email to all co-authors 
and the writing committee had responsibility for approving the final manuscript.
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Introduction 
A fundamental role of the immune system is maintenance of tissue homeostasis by continuous 
immunosurveillance and initiation of inflammatory reactions that involve the coordinated 
activation of innate and adaptive immune cells [1]. Neoplastic transformation alters the orderly 
structure of tissues and induces immune responses that can eliminate incipient tumors. In 
situations where elimination is incomplete neoplastic transformation of cells is able to escape 
immune control. This process has been best conceptualized by the cancer immunoediting 
theory, which is supported by a large body of experimental data and clinical evidence [2]. 
Immunoediting defines malignant progression on the basis of tumor and immune cell interactions 
in three phases: elimination, equilibrium and escape. While patients are most frequently 
diagnosed in the escape phase, this relationship between the tumor and host immunity 
continues to evolve and sometimes with it the magnitude of the anti-tumor immune response. 
Even at advanced disease stages, immune parameters have now been recognized as directly or 
indirectly influencing patient survival [3].   
 
Recently, new therapies that reactivate anticancer immune-responses to cancer, for example in 
melanomas and lung cancer, have entered clinical practice and have improved outcome [47, 
48]. Several recent clinical studies have evaluated the prognostic and predictive importance of 
tumor infiltrating lymphocytes (TILs) in breast cancer (BC). Some of these studies used similar 
methodological approaches for evaluating TILs, which allows for comparison of the results. The 
foreseen inclusion of TILs assessment in current and future clinical studies and diagnostic 
assessments necessitates a detailed description of a standardized methodology.  
 
In December 2013, a group of investigators from around the world representing major breast 
cancer research and clinical teams convened to candidly discuss the important parameters to 
consider as well as methodological obstacles in evaluating TILs in breast cancer. The group 
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recognized the need to provide the breast cancer community with consensus recommendations 
for TILs-evaluation to foster their integration into future clinical trials, translational research and 
diagnostic practice. These efforts may evolve into the establishment of a breast cancer 
“immunological grade”, reflecting the strength of an individual patient’s anti-tumor immune 
response [4]. Here, we outline the current fundamental concepts for TILs-evaluation by 
pathologists to facilitate its widespread use at this stage in our understanding of its relevance for 
breast cancer. The recommendations focus on: 1) what areas to examine in the tumor, 2) how to 
score the TILs and 3) why TILs are clinically important.  
 
What is the composition and role of the immune infiltrate in human breast cancer? 
Immune cells infiltrating tumors are frequently observed, but the composition of cells involved in 
innate and adaptive immunity varies between tumor types or organ sites [5]. Cumulative data 
from murine and human studies have associated most leukocyte subsets with a predominant 
contribution to either pro- or anti-tumor activities (illustrated in Figure 1). Murine models have 
identified myeloid lineage leukocytes, including tumor-associated macrophages, dendritic cells 
and myeloid-derived suppressor cells as playing a central role in shaping the microenvironment 
via the factors they produce, towards either an immuno-stimulatory anti-tumor milieu or a wound 
healing tumor-promoting microenvironment. Anti-tumor T cells migrating into these contrasting 
settings can therefore either be activated or suppressed [6]. In turn, macrophage polarization 
towards pro-tumorigenic M2 or anti-tumor M1 functional phenotypes are regulated by T-
lymphocytes [7], highlighting the importance of cellular cross-talk in shaping the tumor 
microenvironment.  
 
Studies in humans have demonstrated a significant association between the presence of 
specific subsets of immune cells and clinical response in patients with a variety of solid tumors 
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[5]. Furthermore, accumulating evidence suggests that adaptive immunity mediated by T and B 
lymphocytes provides the critical foundation for effective and sustained anti-tumor responses. In 
breast cancer, extensive tumor infiltration by cytotoxic CD8+ T cells was strongly associated with 
patient survival [8, 42] and response to therapy [9]. The presence of CD4+ regulatory T cells 
(Treg) has been associated with both good and bad [10, 11, 12]. Among the other CD4+ T cell 
subpopulations, Th1 cells (the principal cellular source of IFN) have been associated with 
favorable clinical outcomes [13], whereas Th2 cells have been reported to be associated with 
dampening of the anti-tumor response [14]. Th17 cells, producers of the pro-inflammatory IL-17 
cytokine family, appear to have variable effects depending upon the surrounding cytokine milieu, 
which may in part be linked with the organ site and tumor type [15]. The presence of follicular 
helper (Tfh) cells, the newest CD4+ subset, was recently positively associated with patient 
outcome both in the adjuvant and neoadjuvant settings [13]. The precise role of tumor infiltrating 
B cells is currently not well defined and remains controversial [16, 17]. 
 
Given the functional heterogeneity of intratumoral lymphocytes it is intriguing that the degree of 
lymphocytic infiltration assessed by simple evaluation of H&E-stained tumor sections has been 
shown to have predictive and prognostic value in triple negative and HER2+ breast cancer 
despite a lack of detailed information on the immune subpopulations of the infiltrate [18-21]. A 
possible explanation is that negative immune regulators are present as part of a normal 
feedback loop reacting to an active and ongoing anti-tumor immune response, which therefore 
potentially defines tumors that are more immunogenic [22]. This consideration has several 
important implications. The first is that a focused evaluation of individual subsets may have 
limited value. For example, low or absent Treg infiltration may reflect tumors that are 
disregarded by the immune system while high Treg in tumors may signal an active, albeit 
unsuccessful, attempt at tumor rejection. Second, TIL-rich and TIL-poor breast cancers may 
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each reflect a distinct tumor cell biology that likely has markedly different susceptibility to 
immunotherapy. Finally, in moderate to extensively infiltrated  tumors the presence of 
peritumoral or stromal TLS can be seen in some patients [13]. Thus, despite the inability of the 
immune system to reject a clinically detectable tumor, an organized immune response at the 
tumor site may signal the generation of immunological memory with the potential to effectively 
control residual disease. Variability has also been detected within individual tumors [23], 
suggesting that the nature of tumor-immune interactions may parallel tumor heterogeneity.  
Cytotoxic treatments such as chemotherapy and radiotherapy may sometimes act to jump start 
the system [24-26]. In this context, a stronger anti-tumor immune response directed to a broader 
range of BC-antigens would potentially have a higher likelihood of controlling the heterogeneous 
malignant cell population present in large primary tumors and emerging metastases [23]. This 
hypothesis is supported by studies showing that the degree of lymphocyte infiltration is 
predictive of a better local response to neoadjuvant treatment and prognostic of long-term 
disease control [18, 19, 21].  
 
Current data on clinical validity and utility of TILs in breast cancer 
Examples of notable adjuvant and neoadjuvant studies that have assessed infiltrating 
lymphocytes are included in Table 1. In the majority of these studies, both intratumoral and 
stromal TILs have been assessed, with evaluation of the stromal compartment shown to be 
more reproducible between studies.  Some studies focused on TILs using 
immunohistochemistry, while others evaluated molecular markers using immunohistochemistry 
and gene expression analysis. 
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Adjuvant studies  
Triple Negative Breast Cancer (TNBC) 
TILs have been assessed in full face sections of >1300 TNBC and > 3500 hormone-receptor 
positive breast cancers at diagnosis. TILs were found to be a positive prognostic biomarker in 
297 TNBC but not in the luminal subtypes. This correlation was first reported using baseline 
samples from the BIG 2-98 trial [19] and subsequently independently confirmed in 481 TNBC 
sample prospectively collected during two phase III adjuvant randomized BC trials [United States 
Eastern Cooperative Oncology Group (ECOG) trials 2197 and 1199 [21] . Therefore, in TNBC, 
the more stromal TILs a patient has at diagnosis, the better their outcome after adjuvant 
anthracycline-based chemotherapy. Hence, ,according to Simon et al.  [28], the results for the 
prognostic value of TILs in TNBC could be considered Level I evidence. However, given the lack 
of prognostic information for patients with primary TNBC not treated with chemotherapy, TILs 
should not be used as a biomarker for withholding chemotherapy 
HER2+ disease 
Recent data from randomized clinical trials, evaluating TILs on full face sections suggest the 
importance of immunity in HER2+ disease [19, 20].  The FINHER study, where patients were 
randomized to receive received trastuzumab or no trastuzumab, reported that higher TILs in 
baseline samples resulted in higher responses to trastuzumab treatment. Recent data from the 
N9831 study [40] suggested that tumors that were “immune enriched”, as defined using gene 
expression, had better outcomes if they received trastuzumab. While these findings will not 
affect the use of trastuzumab in newly-diagnosed HER2+ breast cancer, they suggest a potential 
mechanism of action for trastuzumab-based therapy. Based on current knowledge, however, 
TILs should not be used to either withhold or prescribe trastuzumab therapy. Given that 
trastuzumab with chemotherapy is the standard of care today, attention has turned to TILs as a 
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prognostic factor in HER2+ disease treated with anti-HER2 therapy [49]. Data suggest that high 
levels of TILs are also associated with excellent outcomes in HER2 disease treated with 
lapatinib as well as dual trastuzumab and lapatinib with chemotherapy (unpublished data). 
 
Neoadjuvant studies 
To date, core biopsies from more than 3000 patients have been assessed for correlation 
between immune markers and response to neoadjuvant chemotherapy, including institutional 
cohorts, but also biomaterials from clinical trials. An overview on the studies is given in Table 1. 
In summary, histological as well as molecular data indicate that immunological parameters, 
including stromal TILs are associated with higher rates of pCR, independent of other clinico-
pathological prognostic factors or the chemotherapy regimen. Intriguingly, an interaction 
between stromal-TILs and a benefit to carboplatin added in the neoadjuvant setting has been 
reported [27], although the biological mechanism remains unclear. 
 
Methodological recommendations for evaluating TILs in Breast Cancer  
Prior to attending the December 2013 meeting, the participants with experience in evaluating 
TILs for phase III studies were asked to complete a questionnaire covering topics pertinent to 
their assessment in breast cancer. These questions are detailed in Supplementary information 1. 
The goal of this approach was to derive a consensus based on current experience within the 
group and use it as the foundation for this guideline. Based on these discussions, the working 
group participants made recommendations for harmonizing TILs-evaluation, which are 
summarized in Table 2. Additionally, a tutorial has been prepared and is included as a 
supplemental data file (Supplementary Tutorial (Supplementary information 2) “Standardized 
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evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer for daily clinical and 
research practice or clinical trial setting”). 
 
Technical issues for evaluation of TILs in Breast Cancer  
1. Microscope magnification does not really make a difference, but usually a magnification of 
200-400 x (ocular 10x, with an objective of 20x-40x) is recommended.  
2. Slide thickness is not critical, with a standard thickness of 4-5 µm considered optimal. The 
majority of existing experience is based on scoring 4-5µm sections of FFPE-tissues, while 
the feasibility of TILs-evaluation on frozen sections is undocumented outside of a research 
setting and thus cannot be recommended for routine use at the present time.  
3. TILs can be evaluated using core biopsies in the neoadjuvant setting as well as surgical 
specimens in the adjuvant setting. Considering all of the above, the scoring of one FFPE-
block/patient is sufficient in the neoadjuvant and adjuvant setting.  Some studies have 
assessed the prognostic or predictive importance of TILs on post-treatment tissues, but 
more studies are needed before formal recommendations can be made on the 
methodology of scoring TILs after neoadjuvant treatment [29]. 
4. Originally, Tissue Microarrays (TMAs) were not recommended for evaluating TILs, since 
there was no published evidence that TMAs mirror the potential heterogeneity of TILs, and 
the number of cores needed and the defined core-diameter, accurately reflecting TIL 
composition in a full section are unknown. However, recently published studies [30, 41, 42] 
using TMAs and well annotated clinical data sets show that results are concordant with 
other studies in the field using mostly biomarker-based determinations of TILs-subsets, not 
H&E determinations of general TILs. TMA’s may be a good option for future studies, 
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particularly for the rapid evaluation of large clinical cohorts. More investigation is needed 
before firm methodological recommendations can be offered. 
5. All mononuclear cells including lymphocytes and plasma cells should be scored 
(granulocytes and other polymorphonuclear leukocytes are excluded). The quantitative 
assessment of other mononuclear cells such as dendritic cells and macrophages is 
currently not recommended, although there is increasing evidence that they may be 
functionally important since they are observed in TLS. 
6. Several studies used immunohistochemistry to assess the clinical importance of subtyping 
lymphocytes. CD45, CD8, CD3 and various other markers expressed on lymphoid cells 
have been tested and while immunohistochemistry may improve accuracy, at the present 
time any added value from these markers is unclear. The TILs working group does not 
currently recommend that immunohistochemistry be used to detect specific subpopulations 
outside of the research setting, until further evidence is available.  
7. Machine scoring approaches, while promising; have not been published in large series 
with consistent methodology. These approaches represent an important area for further 
study.   
8. It is unknown if either RNA or protein classification of TILs by will reveal prognostic and 
predictive value beyond that achievable by simple morphology.  New techniques, like 
CyTOF [44], can review protein based signatures of inflammatory infiltrates.  While these 
are all still in the domain of research, pathologists should be aware of this potential. 
Clinical utility will drive the development of specific immune markers.  
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The concept of stromal vs. intratumoral TILs - focus on the stromal compartment  
The initial studies of breast cancer TILs have evaluated stromal and intratumoral lymphocytes 
separately. Intratumoral TILs are defined as lymphocytes in tumor nests having cell-to-cell 
contact with no intervening stroma and directly interacting with carcinoma cells, while stromal 
TILs are located dispersed in the stroma between the carcinoma cells and do not directly contact 
carcinoma cells. Since both are localized in the region defined as tumor tissue, it should be 
emphasized that both categories represent true TILs. Furthermore, as TILs are able to move 
within a living tissue microenvironment, the distinction may be somewhat artificial and related to 
the static situation in histological slides that are used for diagnostic assessment. The original 
hypothesis was that lymphocytes directly interacting with carcinoma cells might be more relevant 
and therefore more useful for diagnostic assessment. While this hypothesis may still be 
biologically and/or clinically relevant, for diagnostic purposes on H&E-stained sections, most 
current studies have found stromal TILs to be a superior and more reproducible parameter. The 
main reasons are that intratumoral TILs are typically present in lower numbers and detected in 
fewer cases, they are more heterogeneous and are difficult to observe on H&E-stained slides 
(i.e. without using immunohistochemistry or immunofluorescence). Scoring intratumoral TILs 
does not add to the information provided by stromal TILs since they usually parallel stromal TILs. 
However, focusing on the stromal compartment (instead of the tumor as a whole) has a clear 
advantage because the density and growth pattern of carcinoma nests will not affect the TIL 
count because stromal TILs are measured only in the spaces between the carcinoma nests. 
Nevertheless, recent evidence indicates that in the neoadjuvant TNBC setting, and despite the 
methodological reasoning mentioned above, both stromal as well as intratumoral TILs are 
predictive of pathological response to neoadjuvant platinum-based chemotherapy [43]. Also, 
using CD3 or CD8-immunohistochemistry intratumoral TILs may potentially become as easy to 
detect as stromal TILs. Nevertheless, the TILs working group's current recommendation is to 
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evaluate stromal TILs as the principal parameter in future studies, allowing the straightforward 
evaluation of a single parameter. Additional parameters, including TLS in the peritumoral region, 
TILs at the invasive edge or intratumoral TILs can still be included for research purposes to 
further determine and/or confirm their potential clinical relevance.  
 
In the tutorial, evaluations are based on stromal TILs, which are reported in an approximatively 
manner semi-quantitatively on a continuous scale as a percentage of stromal TILs. The working 
group’s consensus is that TILs may provide more biological relevant information when scored as 
a continuous variable, since this will allow more accurate statistical analyses, which can later be 
categorized around different thresholds. However, in daily practice most pathologists will rarely 
report for example 13.5% of TILs and will round up to the nearest 5-10%, in this example thus 
15%.  Pathologist should report their scores in as much detail as the pathologist feels 
comfortable with.  
The original methodology for scoring TILs described by Denkert et al. in 2010 [18] was used in 
the majority of subsequently published studies, thereby providing sufficient data for this initial 
stage in developing a uniform methodology (based on the definitions in Figure 2). Interpersonal 
discussions among pathologists applying this approach since 2010 has slightly modified the 
original version [18] as shown in Figures 3 and 4). While some studies have scored TILs using 
other semi-quantitative approaches [13, 24, 30], the SABCS TILs working group considers the 
clinical validity of the modified Denkert et al. [18] approach described here to be superior at this 
time. This alternative assessment of TILs does of course not invalidate previously published 
findings using other methods of TILs assessment, but provides a framework for future 
standardization.  
 
Using the recommendations in Denkert et al. [18], stromal TILs should be scored uniquely as a 
percentage of the stromal areas alone and areas occupied by carcinoma cells should not be 
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included in the total assessed surface area. This is an important point because otherwise the 
size of the epithelial cell nests as well as the tumor growth pattern could influence the stromal 
TILs value. For example, a score of 50% stromal TILs means that 50% of the stromal surface 
area and thus not stromal nuclei is occupied by TILs and also not 50% of the stroma plus 
epithelial cell area. For semiquantitative assessment of percentage values, the dissociated 
growth pattern of lymphocytes needs to be taken into account. Lymphocytes typically do not 
form solid cellular aggregates, therefore the designation “100% stromal TILs” would still allow 
some empty tissue space between the individual lymphocytes.  
 
 This recommendation is based on the methodology used in published phase III studies, 
implying that there is room for future refinement as evidence accumulates to show the validity of 
alternative parameters and/or methodologies that improve upon this practice. The current 
recommendations are illustrated in Figures 3 and 4 with the methodology fully explained in the 
Supplementary Information (Supplementary Information 2). 
 
The statistical analysis as a non-continuous variable can also be considered as a secondary 
option. For this analysis, the term lymphocyte-predominant breast cancer (LPBC) has been 
coined, which can be used as a descriptive term for tumors that contain “more lymphocytes than 
carcinoma cells”. Typically the threshold of stromal lymphocytes for LPBC is around 50-60% of 
the stromal surface area. Note however that this term should not be used as a definition for a 
specific tumor type, but just as a descriptive term to facilitate discussions about lymphocyte-rich 
tumors. LPBC is not the same as medullary breast cancer, which has additional histological 
features. It is unclear if this cut-off will be used in the future as such dominant TILs infiltration in 
tumors has been found to be infrequent (~10%). 
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Selection of tumor areas for evaluation  
For evaluating TILs, the boundaries of the invasive tumor should be identified with only TILs 
inside them evaluated. TILs in areas with crush artefacts, necrosis, and inflammation around 
biopsy sites or extensive central regressive hyalinization should not be scored. A necrotic biopsy 
is considered unscorable.  
 
Most pathologists recognize that immune infiltrates can also be observed at some distance from 
the main tumor bed, surrounding extra- and intra-tumoral DCIS and also in adjacent normal 
lobules. These infiltrates outside of the tumor borders should not be included in the standardized 
stromal TILs-assessment, but they can be recorded as separate parameters for research 
purposes.  
 
In areas surrounding the tumor, follicular aggregates, although rare can be observed, including 
TLS with germinal centers indicative of an active immune response. These aggregates should 
also not be included in the stromal TILs assessment; however, they can be evaluated separately 
as a research parameter, as they represent areas of T and B cell activation. TLS may become 
important in the future as more evidence emerges on their clinical relevance [13]. In the 
meantime, no formal recommendations for scoring TLS in daily practice can be put forward. TLS 
generally form in the peritumoral regions and therefore may be absent or underrepresented in 
cores or TMAs and heterogeneous in full sections. Furthermore, the criteria for unequivocal 
identification of TLS are currently unclear and the use of IHC may be required. Therefore, at the 
present time TLS should only be assessed in a research setting. 
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Intratumoral heterogeneity and evaluation of the invasive edge 
Based on the collective experience within the TILs working group most tumors are not 
heterogeneous at the morphological level in their TILs content between FFPE-blocks of the 
same tumor, although there is currently no published evidence to support this statement. 
Nevertheless, heterogeneity in a single tissue section can be encountered. The most used 
methodology is global assessment of the slide by a trained pathologist, with a mean infiltrate 
score based on all available tissue being reported. Stromal TILs should be reported as a 
percentage. If the percentage of TILs is questionable, discuss the case with a second 
pathologist. In heterogenous tumors, evaluate different regions and report the average. The 
working group does not recommend focusing on “hot spots”, defined as small areas with 
increased TILs. These small areas are often observed, and they should be included in the 
average TILs-assessment. There is no current evidence demonstrating whether the extent of 
heterogeneity might be clinically important. Since heterogeneity has not yet been investigated 
neither formally characterized either at the morphological nor functional level, the TILs working 
group’s current recommendation, although not formally supported by data is that if there is a 
choice between full sections and core biopsies, whole tissue sections are preferred over core 
biopsies. 
 
There is no current evidence demonstrating that TILs at the invasive edge are functionally 
different from TILs in the center of the tumor. Based on this lack of knowledge, it was suggested 
that scoring TILs at the invasive edge as a separate parameter from TILs located in the inner 
stroma should at the present time merely be done in a research setting. In daily practice a 
distinction should not be made and all TILs within the tumor boundaries, including the invasive 
edge should be scored together as stromal TILs.  
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Inter- and intra-laboratory assessment, thresholds and machine learning algorithms 
Most published or ongoing unpublished studies have not formally assessed intra-personal and 
inter-personal differences in scoring slides by pathologists. The accepted intra- and inter-
personal discordance between pathologists depends on the clinical use/consequences of the 
measurements. The total allowable margin of error between pathologists will thus need to be 
determined in accordance with the clinical validity and utility of this methodology. It should be 
emphasized that if the primary purpose is to find an approach for daily practice, the impact on 
daily routine should be minimal without a significant increase in the pathologist’s time. A tutorial 
to help pathologists evaluate TILs accompanies this paper. 
 
At present, there are no established thresholds for TILs. The consensus of the group was that a 
valid methodology was top priority and that thresholds for clinical decision can be determined 
once a solid methodology with clinical utility is in place. Therefore, there are currently no 
recommendations for the best threshold in clinical practice. We recommend that TILs be 
analyzed as a continuous variable unless it is clear that the prognostic information is not linearly 
associated with increasing levels of TILs. Further research will determine whether a threshold is 
required. We again emphasize that the level of TILs should not be used to withhold 
chemotherapy or trastuzumab therapy in TN and HER2+ BC, respectively. 
The assessment of TILs by digital image analysis might be useful for standardization in the 
future, since this approach has the potential, for example, to determine the number of TILs per 
mm² stromal tissue as an exact measurement contrary to the approximate semi-quantitative 
evaluation suggested at this moment. Based on the standardized methodology recommended 
here (summarized in Table 2), an inter-laboratory Ring study will be initiated to assess the 
reproducibility and clinical validity of TILs assessment, including machine learning algorithms.  
 at K
U
 Leuven U
niversity Library on Septem
ber 13, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
21 
 
Future Directions 
This article has focused on a standardized approach for measuring the percentage of stromal 
TILs in primary tumor specimens prior to therapy, using visual assessment of standard H&E-
stained sections. Our goal is to facilitate the use of TILs as a biomarker in research and clinical 
trial settings (i.e. as a stratification or adjustment factor). This should also provide a platform for 
pathologists to further engage in an effort for the harmonization of the assay. 
 
While it may be argued that stromal TILs are a robust prognostic factor in TNBC treated with 
standard adjuvant anthracycline-based chemotherapy, with three published prospective 
validation studies currently provide level I evidence for its clinical validity, we do not yet advocate 
that adjuvant treatment decisions be based on the level of TILs in the baseline TNBC neither on 
HER2+ cancer samples because the analytical validity and clinical utility of TILs in these 
subtypes remains to be firmly determined. We are yet to determine if TILs will be predictive of 
response to immunotherapeutic regimens, in particular T-cell checkpoint inhibition, which 
ultimately may be its clinical utility. 
 
While TILs have been measured morphologically and have been shown to add predominantly 
prognostic information, methodological open questions in the morphological evaluation of TILs 
still remain (Supplementary Information 3 and Supplementary Figure 1). The measurement on 
H&E-stained slides most likely represents the beginning of the efforts to use infiltrating cell 
properties as companion diagnostic tests. The huge complexity of lymphocytes, both from the 
standpoint of cell type and activation suggests that molecular characterization of this infiltrate 
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may add both sensitivity and specificity to the predictive value of morphologically defined TILs 
[45, 46].  Thus, as a field, we should be open to the introduction of molecular methods, most 
likely in situ, that can classify the TILs-component.  However, at this time, these molecular 
methods are still experimental and not sufficiently documented for introduction into standard 
practice. 
 
Further scientific questions concerning the underlying breast cancer pathology associated with 
higher levels of TILs at diagnosis, the relevance of TILs subtyping and what can be done 
clinically to enhance host anti-tumor immune responses have not been addressed at present. As 
our understanding evolves and clinical evidence accumulates, some of the methodological 
statements provided in these 2014 guidelines will be updated in subsequent articles. 
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Table and Figure Legends 
Table 1 
Adjuvant and neoadjuvant studies that have assessed TILs and prognosis are included in Table 
1 
Table 2  
Recommendations for assessing tumor-infiltrating lymphocytes (TILs) in breast cancer 
 
Figure 1 
The cellular crosstalk between different leukocyte subsets and their predominant contribution to 
either pro- or anti-tumor activities, including myeloid lineage leukocytes, tumor-associated 
macrophages with either pro-tumorigenic (M2) or anti-tumorigenic (M1) properties, helper T cell 
subsets, cytotoxic T cells, regulatory T-cells, B cells, dendritic cells and myeloid-derived 
suppressor cells are shown. These cells play central roles in shaping the microenvironment via 
the factors they produce thereby driving either an immune mediated anti- or pro-tumor activities 
in the microenvironment. 
Figure 2 
Morphology, definitions, biological and diagnostic relevance of the different immune infiltrates 
found in breast cancer.  
Figure 3  
Standardized approach for TILs-evaluation in Breast Cancer 
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Figure 4 
Standardisation and guidelines for TILs-assessment. Stromal TILs should be reported as a 
percentage (the schematic images might provide some guidance). If the percentage of TILs is 
questionable, discuss the case with a second pathologist. In heterogenous tumors, evaluate 
different regions and report the average. For this standardized graphic, images were selected 
that are representative of different TILs- levels, based on the results of three pathologists as well 
as image analysis. The stromal area was marked in each image. The central images are digitally 
generated graphics showing the same ROI (Region Of Interest) and a similar density of TILs as 
the corresponding histological image. Please note that the central images contain idealized TILs 
generated graphically with comparably density, but not with the exact configuration and 
distribution as the TILs in the histological images. 
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Table 1 Overview of adjuvant and neoadjuvant studies 
Adjuvant studies 
Reference  Study (level 
of evidence 
if applicable 
according 
to Simon et 
al [28] 
Regimen  Tumor tissue  
Assay  
Sample 
size 
Correlation with 
outcome   
[19] BIG 02-98 
(category B) 
ACMF or  
ACCMF  
Full section 
H&E 
2009 total None 
256 TNBC Stromal TILs (sTIL) 
(continuous, per 10% 
increase) univariate:    
HR 0.84 (p=0.02, DFS) 
HR 0.82 (p=0.02, OS) 
sTIL multivariate: 
HR 0.85 (p=0.02, DFS) 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
HR 0.83 (p=0.02, OS) 
297 
HER2+ 
None 
1078 HR+ None 
 [21] E2197 
E1199 
(category B) 
AC vs AC 
AC  
Docetaxel 
or 
paclitaxel 
Full section  
H&E  
481 TNBC 
sTIL (continuous, per 
10% increase)   
Univariate:  
HR 0.86 (p=0.02, DFS) 
HR 0.81 (p=0.01, OS) 
Multivariate: 
HR 0.84 (p=0.005, 
DFS) 
HR 0.79 (p=0.003, OS) 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
[20] 
 
FINHER 
(category B) 
Docetaxel 
or 
Vinorelbine 
 FEC 
With 
trastuzuma
b if HER2+) 
Full section 
H&E 
934 total None 
134 TNBC 
sTIL (continuous, per 
10% increase)  
Univariate: 
HR 0.79 (p=0.03, 
DDFS) 
HR 0.80 (p=0.08, OS) 
Multivariate: 
HR 0.77 (p=0.02, 
DDFS) 
HR 0.81 (p=0.14, OS) 
209 
HER2+ 
sTIL (continuous, per 
10% increase) correlate 
with DDFS (HR 0.82, 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
p=0.025 univariate ) 
only with trastuzumab, 
not OS. 
591 HR+ None 
[41] Four studies 
Including 
NEAT 
clinical trial 
(category B) 
 TMA 
CD8, FOXP3 
immunohisto-
chemistry 
12,439 CD8+ T Cells in tumor 
and stroma was 
associated with 28% 
and 21% reduced risk 
of BCSS. Greater 
benefit in ER-negative 
disease and 
ER=/HER2 
[8] Consecutive  CMF  TMA  
CD8-
immunohisto- 
chemistry 
1334 Binary high versus low: 
Total CD8 correlates 
with BCSS (HR 0.55, 
p=0.001multivariate-
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
training set; HR: 0.58, 
p<0.002 multivariate-
validation set) 
[51] Consecutive  MF, AC, 
FAC or no 
chemother
apy 
TMA  
CD8-
immunohisto- 
chemistry 
1985 HR+ None 
216 
HER2+ 
None 
496 TNBC Binary any versus 
none: CD8 correlates 
with BCSS, multivariate 
iTIL (intratumoral TILs) 
HR 0.48, p<0.001 
[30] Institutional Varied- 
chemother
apy not 
specified 
PD-L1 mRNA 
TILs 
636 
Higher PD-L1 mRNA 
associated with better 
recurrence-free 
survival. 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
PD-L1 mRNA 
correlated with TILs 
[32] Consecutive  CMF, AC, 
CEF or 
CAF  
TMA  
CD3-
immunohisto-
chemistry 
255 
Binary high versus low 
total CD3 correlates 
with DFS in 
anthracycline group 
(HR 0.25, p=0.0056) 
Neoadjuvant studies  
Reference  Study  Regimen  Tumor 
tissue  
Assay  
Sample 
size 
Correlation with 
outcome  
 [31] Institutional cohort anthracycline- 
taxane-based 
regimens 
CD3-
immunohisto
chemistry 
73 CD3 positively 
correlated with pCR 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
[18] GeparDuo GeparTrio  
(category B) 
EC-Doc 
(GeparDuo) 
TAC +/-
Vinorelbine/C
apecitabine 
(GeparTrio) 
TILs in H&E 
core biopsy  
1058 
 
 
Stromal TILs and LPBC 
associated (p=0.001) 
with pCR 
TILs significant in 
subgroups (HR+/-; 
HER2+/-) 
 
 [32] Publicly available gene expression data 
from  EORTC 10994/BIG 00-01 
FEC vs TET Gene 
expression 
data 
113 
ER- 
TILS correlate with 
pCR (p=0.001) 
 [33] 
 
Institutional cohort Neoadjuvant 
anthracycline-
based; 
cyclophospha
mide-based or 
taxane-based 
regimens 
TILs in H&E 
core biopsy 
474 total 
92 TNBC 
TILs correlate with pCR 
in TNBC (p=0.004) 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
[34] 
 
Institutional cohort Neoadjuvant 
anthracycline- 
taxane-based 
regimens 
TILs in H&E 
core biopsy 
68  TILs correlate with pCR 
(p<0.0001) 
[35] 
 
Institutional cohort Neoadjuvant 
paclitaxel FEC 
CD8, 
FOXP3, 
IL17F 
immunohisto
chemistry 
180 CD8, FOXP3 positively 
correlated with pCR 
(p<0.001) 
[36] 
 
Publicly available gene expression data (7 
cohorts) 
Anthracycline-
based 
neoadjuvant 
therapy 
IGKC gene 
expression 
845 IGKC predicted 
response to NACT 
(p<0.001) 
[37] 
 
  
GeparQuinto Predict clinical study 
(category B) 
EC-Doc Core biopsy  
H&E 
313 
HER2 
negative 
Stromal TILs and LPBC 
associated with pCR 
(p<0.001) 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
[9] 
 
 
Institutional cohort Neoadjuvant 
anthracycline- 
taxane-based 
regimens 
CD8, CD4, 
FOXP3 
immunohisto
chemistry 
153 CD8, CD4, FOXP3 
positively correlated 
with pCR (p=0.003, 
p<0.001 and p=0.001) 
 
[38] 
 
 
 
Institutional cohort Neoadjuvant 
anthracycline- 
taxane-based 
regimens 
TILs by 
H&E; CD3, 
CD8, 
FOXP3 
immunohisto
chemistry 
175 TILs, CD3, CD8, 
FOXP3 positively 
correlated with pCR   
[39] 
  
TVA  neoadjuvant phase 2 study 4FEC100 +- 4 
docetaxel + 
panitumumab 
CD8 
immunohisto
chemistry 
47 TNBC High CD8/FoxP3 were 
predictive of pCR 
[50] Pooled analysis of publicly available gene 
expression data (8 cohorts) 
Neoadjuvant 
anthracycline 
STAT1 and 
immune 
996 High score of STAT1 
and immune response 
 at KU Leuven University Library on September 13, 2014 http://annonc.oxfordjournals.org/ Downloaded from 
  
 
 
 
 
 
 
/ 
anthracycline 
+ taxane 
based 
chemotherapy 
response 
gene 
modules 
gene modules is 
associated with 
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Table 2 Recommendations for assessing tumor-infiltrating lymphocytes (TILs) in breast 
cancer 
1. TILs should be reported for the stromal compartment (= % stromal TILs). The 
denominator used to determine the % stromal TILs is the area of stromal tissue (i.e. area 
occupied by mononuclear inflammatory cells over total intratumoral stromal area), not the 
number of stromal cells (i.e. fraction of total stromal nuclei that represent mononuclear 
inflammatory cell nuclei).  
2. TILs should be evaluated within the borders of the invasive tumor. 
3. Exclude TILs outside of the tumor borders, e.g. around DCIS and normal lobules. 
4. Exclude TILs in tumor zones with crush artefacts, necrosis, regressive hyalinization as 
well as in the previous core biopsy site. 
5. All mononuclear cells (including lymphocytes and plasma cells) should be scored, but 
polymorphonuclear leukocytes are excluded. 
6. 1 section (4-5 µm, magnification 200-400x) per patient is currently considered to be 
sufficient.  
7. Full sections are preferred over biopsies whenever possible. Cores can be used in the 
pre-therapeutic neoadjuvant setting; currently no validated methodology has been 
developed to score TILs after neo-adjuvant treatment.  
8. A full assessment of average TILs in the tumor area by the pathologist should be used. 
Do not focus on hotspots.  
9. The working group’s consensus is that TILs may provide more biological relevant 
information when scored as a continuous variable, since this will allow more accurate 
statistical analyses, which can later be categorized around different thresholds. However, 
in daily practice most pathologists will rarely report for example 13.5% and will round up 
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to the nearest 5-10%, in this example thus 15%.  Pathologist should report their scores in 
as much detail as the pathologist feels comfortable with. 
10. TILs should be assessed as a continuous parameter.  The percentage of stromal TILs is 
a semiquantitative parameter for this assessment, for example, 80% stromal TILs means 
that 80% of the stromal area shows a dense mononuclear infiltrate. For assessment of 
percentage values, the dissociated growth pattern of lymphocytes needs to be taken into 
account. Lymphocytes typically do not form solid cellular aggregates, therefore the 
designation “100% stromal TILs” would still allow some empty tissue space between the 
individual lymphocytes.  
11. No formal recommendation for a clinically relevant TIL threshold(s) can be given at this 
stage. The consensus was that a valid methodology is currently more important than 
issues of thresholds for clinical use, which will be determined once a solid methodology 
is in place. LPBC (lymphocyte predominant breast cancer) can be used as a descriptive 
term for tumors that contain “more lymphocytes than tumor cells”. However, the 
thresholds vary between 50-60% stromal lymphocytes. 
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